5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design
    Meeting Abstract

    Kyriakopoulos, C.; Chatta, G. S.; Laccetti, A. L.; Iannotti, N.; Sokolova, A.; Hotte, S. J.; Tutrone, R. F.; Markowski, M. C.; Nordquist, L. T.; Pili, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study
    Meeting Abstract

    Shore, N. D.; Sieber, P. R.; Gleave, M.; De Giorgi, U.; Mehlhaff, B. A.; Danila, D. C.; Dunshee, C.; Lallas, C. D.; Pliskin, M.; Tang, Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D. W.; Lakhani, N. J.; Hawley, J. E.; Aparicio, A.; Narayan, V.; Srinivas, S.; Runcie, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study
    Meeting Abstract

    Rathkopf, D. E.; Roubaud, G.; Chi, K. N.; Efstathiou, E.; Attard, G.; Olmos, D.; Small, E. J.; Saad, M.; Castro, E.; Kim, W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study
    Meeting Abstract

    Voss, M. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Genomic profiling of bladder cancer in waterpipe and cigarette smokers: Implications for carcinogenicity and genetic landscape
    Meeting Abstract

    Shamseddine, A.; Abbas, N.; Chatila, W. K.; Walch, H. S.; Eichholz, J.; Schultz, N.; Solit, D. B.; Charafeddine, M.; Al Darazi, M.; Abou-Alfa, G. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
    Meeting Abstract

    Deming, D. A.; Kwiatkowski, D. J.; Ding, L.; Schmid, A. N.; Navarro, W. H.; Ahnert, J. R.; Iyer, G.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world analysis of patients with advanced gastrointestinal (GI) cancers harboring inactivating TSC1 and TSC2 alterations using the Foundation Medicine genomic database
    Meeting Abstract

    Deming, D. A.; Palma, N. A.; Navarro, W. H.; Iyer, G.; Kwiatkowski, D. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS
    Meeting Abstract

    Cytryn, S. L.; Phu, W.; Shah, R. H.; Walch, H. S.; Chatila, W. K.; Vakiani, E.; Brannon, A. R.; Ladanyi, M.; Srivastava, A.; Tang, L. H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress)
    Meeting Abstract

    Powles, T.; Grande, E.; Van Der Heijden, M.; Necchi, A.; Iyer, G.; Drakaki, A.; Loriot, Y.; Sokolowski, K.; Zhang, W.; Galsky, M.
    European Urology (2024)

    Fulltext@MSK | Save